A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZEDSTUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS.CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVEMETASTATIC BREAST CANCER
A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZEDSTUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS.CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVEMETASTATIC BREAST CANCER
A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evaluate the anti-tumor activity of the combination therapyEstudio de prueba de concepto en fase II, aleatorizado, abierto de WX-671 en combinación con gemcitabina frente a gemcitabina sola en pacientes con cáncer de páncreas localmente avanzado no resecable cuyo objetivo es evaluar la actividad antitumoral de la terapia en combinación